ATE317269T1 - Methoden und zusammensetzungen zur erhöhung der immunantwort und zur herstellung von in-vitro monoklonalen antikörpern (mabs) - Google Patents
Methoden und zusammensetzungen zur erhöhung der immunantwort und zur herstellung von in-vitro monoklonalen antikörpern (mabs)Info
- Publication number
- ATE317269T1 ATE317269T1 AT98958518T AT98958518T ATE317269T1 AT E317269 T1 ATE317269 T1 AT E317269T1 AT 98958518 T AT98958518 T AT 98958518T AT 98958518 T AT98958518 T AT 98958518T AT E317269 T1 ATE317269 T1 AT E317269T1
- Authority
- AT
- Austria
- Prior art keywords
- specific
- methods
- cells
- compositions
- monoclonal antibodies
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 238000000338 in vitro Methods 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 230000028993 immune response Effects 0.000 title abstract 2
- 239000000427 antigen Substances 0.000 abstract 3
- 102000036639 antigens Human genes 0.000 abstract 3
- 108091007433 antigens Proteins 0.000 abstract 3
- 239000003022 immunostimulating agent Substances 0.000 abstract 3
- 210000002540 macrophage Anatomy 0.000 abstract 2
- 229960005486 vaccine Drugs 0.000 abstract 2
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 210000003719 b-lymphocyte Anatomy 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 238000006243 chemical reaction Methods 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 abstract 1
- 239000010931 gold Substances 0.000 abstract 1
- 229910052737 gold Inorganic materials 0.000 abstract 1
- 210000002865 immune cell Anatomy 0.000 abstract 1
- 210000000987 immune system Anatomy 0.000 abstract 1
- 210000004698 lymphocyte Anatomy 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Ceramic Engineering (AREA)
- Transplantation (AREA)
- Genetics & Genomics (AREA)
- Nanotechnology (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6515597P | 1997-11-10 | 1997-11-10 | |
| US7581198P | 1998-02-24 | 1998-02-24 | |
| US10745598P | 1998-11-06 | 1998-11-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE317269T1 true ATE317269T1 (de) | 2006-02-15 |
Family
ID=27370737
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT98958518T ATE317269T1 (de) | 1997-11-10 | 1998-11-10 | Methoden und zusammensetzungen zur erhöhung der immunantwort und zur herstellung von in-vitro monoklonalen antikörpern (mabs) |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP1039933B8 (enExample) |
| JP (3) | JP4588210B2 (enExample) |
| AT (1) | ATE317269T1 (enExample) |
| AU (3) | AU757357B2 (enExample) |
| CA (1) | CA2309602C (enExample) |
| DE (1) | DE69833455T2 (enExample) |
| NZ (1) | NZ504292A (enExample) |
| WO (1) | WO1999024066A2 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20010055581A1 (en) | 1994-03-18 | 2001-12-27 | Lawrence Tamarkin | Composition and method for delivery of biologically-active factors |
| US7229841B2 (en) | 2001-04-30 | 2007-06-12 | Cytimmune Sciences, Inc. | Colloidal metal compositions and methods |
| US6407218B1 (en) | 1997-11-10 | 2002-06-18 | Cytimmune Sciences, Inc. | Method and compositions for enhancing immune response and for the production of in vitro mabs |
| EP1133994A1 (en) * | 2000-03-11 | 2001-09-19 | Biognostik Gesellschaft für biomolekulare Diagnostik mbH | A method for reversing the immunosuppressive effects of the Melanoma Inhibitory Activity "MIA" |
| JP5175020B2 (ja) * | 2001-04-30 | 2013-04-03 | サイティミューン サイエンシーズ， インコーポレイテッド | コロイド状金属組成物および方法 |
| AU2004311630A1 (en) | 2003-12-02 | 2005-07-21 | Cytimmune Sciences, Inc. | Methods and compositions for the production of monoclonal antibodies |
| US20050175584A1 (en) * | 2004-01-28 | 2005-08-11 | Paciotti Giulio F. | Functionalized colloidal metal compositions and methods |
| KR100836745B1 (ko) * | 2007-01-31 | 2008-06-10 | (주)두비엘 | Ｈｂｖ 백신 및 그의 제조 방법 |
| US8877156B2 (en) | 2007-06-26 | 2014-11-04 | New York University | Contrast agents anchored by thiols on nanoparticles |
| AU2008302035A1 (en) * | 2007-09-21 | 2009-03-26 | Cytimmune Sciences, Inc. | Nanotherapeutic colloidal metal compositions and methods |
| CA2706700A1 (en) | 2007-11-08 | 2009-05-14 | Cytimmune Sciences, Inc. | Compositions and methods for generating antibodies |
| JP5364310B2 (ja) * | 2008-07-14 | 2013-12-11 | アルフレッサファーマ株式会社 | 反応性物質が結合した微小粒子の安定化方法および該微小粒子含有試薬 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS57502090A (enExample) * | 1980-07-18 | 1982-11-25 | ||
| CA1214123A (en) * | 1983-01-20 | 1986-11-18 | Masashi Matsui | Cell lines for use in the preparation of hybridoma cells |
| JPS61104796A (ja) * | 1984-10-26 | 1986-05-23 | Chemo Sero Therapeut Res Inst | モノクロ−ナル抗体の製造方法 |
| JPS62162963A (ja) * | 1986-01-10 | 1987-07-18 | Sadao Shiosaka | 金属コロイド粒子を担体とする低分子物質に対する特異抗体の作成法 |
| ATE270111T1 (de) * | 1993-03-18 | 2004-07-15 | Cytimmune Sciences Inc | Zusammensetzung und methode zur reduktion der toxizität von biologisch-aktiven faktoren |
| JPH07227299A (ja) * | 1994-02-14 | 1995-08-29 | Kyoto Daiichi Kagaku:Kk | Ｄｎａの特定塩基配列の検出方法及びその装置 |
| US5686578A (en) * | 1994-08-05 | 1997-11-11 | Immunomedics, Inc. | Polyspecific immunoconjugates and antibody composites for targeting the multidrug resistant phenotype |
| JPH09107980A (ja) * | 1995-08-17 | 1997-04-28 | Japan Tobacco Inc | 新規生理活性タンパク |
| US6407218B1 (en) * | 1997-11-10 | 2002-06-18 | Cytimmune Sciences, Inc. | Method and compositions for enhancing immune response and for the production of in vitro mabs |
| ATE320270T1 (de) * | 1997-11-10 | 2006-04-15 | Cytimmune Sciences Inc | Zusammensetzungen und methoden zur zielgerichteten abgabe von biologisch aktivenfaktoren |
-
1998
- 1998-11-10 AT AT98958518T patent/ATE317269T1/de active
- 1998-11-10 WO PCT/US1998/023957 patent/WO1999024066A2/en not_active Ceased
- 1998-11-10 AU AU14548/99A patent/AU757357B2/en not_active Ceased
- 1998-11-10 EP EP98958518A patent/EP1039933B8/en not_active Expired - Lifetime
- 1998-11-10 NZ NZ504292A patent/NZ504292A/xx not_active IP Right Cessation
- 1998-11-10 JP JP2000520153A patent/JP4588210B2/ja not_active Expired - Fee Related
- 1998-11-10 CA CA2309602A patent/CA2309602C/en not_active Expired - Fee Related
- 1998-11-10 DE DE69833455T patent/DE69833455T2/de not_active Expired - Lifetime
-
2003
- 2003-05-23 AU AU2003204353A patent/AU2003204353B2/en not_active Ceased
-
2006
- 2006-11-10 AU AU2006235956A patent/AU2006235956B2/en not_active Ceased
-
2009
- 2009-06-17 JP JP2009144707A patent/JP2009292818A/ja active Pending
-
2012
- 2012-09-27 JP JP2012214639A patent/JP2013014616A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| DE69833455D1 (de) | 2006-04-20 |
| WO1999024066A3 (en) | 1999-12-09 |
| AU2006235956B2 (en) | 2010-02-11 |
| EP1039933A2 (en) | 2000-10-04 |
| AU757357B2 (en) | 2003-02-20 |
| WO1999024066A2 (en) | 1999-05-20 |
| DE69833455T2 (de) | 2006-10-19 |
| EP1039933B1 (en) | 2006-02-08 |
| JP2009292818A (ja) | 2009-12-17 |
| JP4588210B2 (ja) | 2010-11-24 |
| NZ504292A (en) | 2003-03-28 |
| AU2006235956A1 (en) | 2006-11-30 |
| AU2003204353B2 (en) | 2006-08-10 |
| JP2013014616A (ja) | 2013-01-24 |
| CA2309602A1 (en) | 1999-05-20 |
| JP2002503639A (ja) | 2002-02-05 |
| AU1454899A (en) | 1999-05-31 |
| CA2309602C (en) | 2011-04-26 |
| EP1039933B8 (en) | 2006-12-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR9809656A (pt) | Composição imunopotencializante | |
| ATE317269T1 (de) | Methoden und zusammensetzungen zur erhöhung der immunantwort und zur herstellung von in-vitro monoklonalen antikörpern (mabs) | |
| CA2290485A1 (en) | Method for the production of non-immunogenic proteins | |
| EP1077719A4 (en) | VACCINE DELIVERY SYSTEM | |
| ATE397456T1 (de) | Enterokokkus antigene und vakzine | |
| PL343245A1 (en) | Methods for identifying inducers and inhibitors of proteolytic antibodies, compositions and their uses | |
| IL142948A0 (en) | Agents and compositions and methods utilizing same useful in diagnosing and/or treating or preventing plaque forming diseases | |
| ID30497A (id) | Peptida hiv, antigen, komposisi vaksin, kit imunoasai dan metoda untuk mendeteksi antibodi yang diinduksi oleh hiv | |
| DE69929444D1 (de) | Cpg-zusammensetzungen, saponin-adjuvantien und verfahren zu deren verwendung | |
| IL107026A0 (en) | Antigen of hybrid m protein and carrier for group a streptococcal vaccine | |
| PL330794A1 (en) | Polypeptides capable of forming structures bonding an antigen exhibiting antigenic specificity in respect to antigenes rh d, dna sequences coding such polypeptides and method of producing and using them | |
| ATE233102T1 (de) | Verfahren und zusammensetzung zur umgestaltung multi-epitopischer antigene um die immunantwort einzuleiten | |
| ES2196150T3 (es) | Induccion de tolerancia inmunologica por el uso de anticuerpos anti-cd4 que no inducen deplecion. | |
| IL122233A0 (en) | Monoclonal antibodies their production and pharmaceutical compositions and diagnostic reagents containing them | |
| ATE442439T1 (de) | Melanoma antigene p15 und deren anwendung in diagnostischen und therapeutischen verfahren | |
| ATE398137T1 (de) | Porphyromonas gingivalis antigene zur diagnose und behandlung von periodontitis | |
| ATE96675T1 (de) | Spezifische sekretions-exkretions-antigene von toxoplasma gondii, deren expressionsprodukte, verfahren zu deren herstellung und deren diagnostische und prophylaktische anwendungen. | |
| MXPA03008587A (es) | Metodo para producir una vacuna. | |
| WO2004033483A3 (en) | Liposomal system and method of using same | |
| DK0513565T3 (da) | Monoklonale antistoffer mod plasmin-antiplasmin-komplekset, fremgangsmåde til deres fremstilling og deres anvendelse | |
| Zan‐Bar et al. | The relationship between surface immunoglobulin isotype and immune function of murine B lymphocytes V. IgD‐bearing cells in immunological tolerance | |
| AU2579600A (en) | Product and method for obtaining specific immunisation with one or more antigens | |
| IT8821547A0 (it) | Metodo immunologico per la determinazione di anticorpi anti antigeni di microorganismi, mediante anticorpi antiidiotipo e mezzi adatti allo scopo. | |
| MX9707295A (es) | Metodo para mejorar la respuesta de los anticuerpos a los antigenos especificos con interleucina-10. | |
| BR9711809A (pt) | Polipeptìdeo antigênico ou imunogênico, processos para tratar ou prevenir uma doença ou distúrbio em um indivìduo provocado por infecção com htlv-i, e com htlv-ii, para elicitar em um indivìduo a produção de anticorpos que especificamente ligam-se às proteìnas envelopes htlv-ii e htlv-i, e, para gerar uma resposta imune em um indivìduo |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1039933 Country of ref document: EP |